MedKoo Cat#: 555445 | Name: NLX-204 HCl
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

NLX-204 is a potent and selective ERK1/2 phosphorylation-preferring serotonin 5 HT1A receptor agonist with pKi = 10.19. NLX-204 displayed high selectivity in the SafetyScreen44 panel (including hERG channel), high solubility, metabolic stability, and Caco-2 penetration and did not block CYP3A4, CYP2D6 isoenzymes, or P-glycoprotein. Preliminary in vivo studies confirmed its promising pharmacokinetic profile. NLX-204 also robustly stimulated ERK1/2 phosphorylation in rat cortex and showed highly potent (MED = 0.16 mg/kg) and efficacious antidepressant-like activity, totally eliminating immobility in the rat Porsolt test.

Chemical Structure

NLX-204 HCl
CAS#2170405-10-2 (free base)

Theoretical Analysis

MedKoo Cat#: 555445

Name: NLX-204 HCl

CAS#: 2170405-10-2 (free base)

Chemical Formula: C20H23Cl2F2N3O2

Exact Mass: 0.0000

Molecular Weight: 445.11

Elemental Analysis: C, 53.82; H, 5.19; Cl, 15.89; F, 8.51; N, 9.41; O, 7.17

Price and Availability

Size Price Availability Quantity
25mg USD 550.00 2 Weeks
50mg USD 950.00 2 Weeks
100mg USD 1,650.00 2 Weeks
200mg USD 2,650.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
Synonym
NLX-204; NLX204; NLX204; NLX-204 HCl; NLX-204 hydrochloride;
IUPAC/Chemical Name
(3-chloro-4-fluorophenyl)(4-fluoro-4-(((2-(pyridin-2-yloxy)ethyl)amino)methyl)piperidin-1-yl)methanone hydrochloride
InChi Key
ANOJKCJEWKVZDV-UHFFFAOYSA-N
InChi Code
InChI=1S/C20H22ClF2N3O2.ClH/c21-16-13-15(4-5-17(16)22)19(27)26-10-6-20(23,7-11-26)14-24-9-12-28-18-3-1-2-8-25-18;/h1-5,8,13,24H,6-7,9-12,14H2;1H
SMILES Code
O=C(C1=CC=C(F)C(Cl)=C1)N2CCC(CNCCOC3=NC=CC=C3)(F)CC2.[H]Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Biological target:
NLX-204 is a potent and selective ERK1/2 phosphorylation-preferring serotonin 5 HT1A receptor agonist with pKi = 10.19.
In vitro activity:
The lead structure, (3-chloro-4-fluorophenyl)(4-fluoro-4-(((2-(pyridin-2-yloxy)ethyl)amino)methyl)piperidin-1-yl)methanone (17, NLX-204), displayed high selectivity in the SafetyScreen44 panel (including hERG channel), high solubility, metabolic stability, and Caco-2 penetration and did not block CYP3A4, CYP2D6 isoenzymes, or P-glycoprotein. Reference: J Med Chem. 2019 Mar 14;62(5):2750-2771. https://pubmed.ncbi.nlm.nih.gov/30721053/
In vivo activity:
NLX-204 reduced depressive-like behavior in the FST in CORT and UCMS mice, and normalized sucrose preference in CORT mice, suggesting anti-anhedonic activity. NLX-204 increased pERK1/2 levels in PFC of UCMS mice. NLX-204 also increased pCREB levels in PFC of CORT mice. These data suggest that NLX-204 has RAAD-like properties not only in naïve mice, but also in mice in a "depressive-like" state, and that these involve changes in PFC and hippocampal pERK1/2 and pCREB levels. Reference: Behav Brain Res. 2023 Feb 13;438:114207. https://pubmed.ncbi.nlm.nih.gov/36368443/

Preparing Stock Solutions

The following data is based on the product molecular weight 445.11 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Sniecikowska J, Gluch-Lutwin M, Bucki A, Więckowska A, Siwek A, Jastrzebska-Wiesek M, Partyka A, Wilczyńska D, Pytka K, Pociecha K, Cios A, Wyska E, Wesołowska A, Pawłowski M, Varney MA, Newman-Tancredi A, Kolaczkowski M. Novel Aryloxyethyl Derivatives of 1-(1-Benzoylpiperidin-4-yl)methanamine as the Extracellular Regulated Kinases 1/2 (ERK1/2) Phosphorylation-Preferring Serotonin 5-HT1A Receptor-Biased Agonists with Robust Antidepressant-like Activity. J Med Chem. 2019 Mar 14;62(5):2750-2771. doi: 10.1021/acs.jmedchem.9b00062. Epub 2019 Mar 2. PMID: 30721053. 2. Głuch-Lutwin M, Sałaciak K, Pytka K, Gawalska A, Jamrozik M, Śniecikowska J, Kołaczkowski M, Depoortère RY, Newman-Tancredi A. The 5-HT1A receptor biased agonist, NLX-204, shows rapid-acting antidepressant-like properties and neurochemical changes in two mouse models of depression. Behav Brain Res. 2023 Feb 13;438:114207. doi: 10.1016/j.bbr.2022.114207. Epub 2022 Nov 8. PMID: 36368443.
In vitro protocol:
1. Sniecikowska J, Gluch-Lutwin M, Bucki A, Więckowska A, Siwek A, Jastrzebska-Wiesek M, Partyka A, Wilczyńska D, Pytka K, Pociecha K, Cios A, Wyska E, Wesołowska A, Pawłowski M, Varney MA, Newman-Tancredi A, Kolaczkowski M. Novel Aryloxyethyl Derivatives of 1-(1-Benzoylpiperidin-4-yl)methanamine as the Extracellular Regulated Kinases 1/2 (ERK1/2) Phosphorylation-Preferring Serotonin 5-HT1A Receptor-Biased Agonists with Robust Antidepressant-like Activity. J Med Chem. 2019 Mar 14;62(5):2750-2771. doi: 10.1021/acs.jmedchem.9b00062. Epub 2019 Mar 2. PMID: 30721053.
In vivo protocol:
1. Głuch-Lutwin M, Sałaciak K, Pytka K, Gawalska A, Jamrozik M, Śniecikowska J, Kołaczkowski M, Depoortère RY, Newman-Tancredi A. The 5-HT1A receptor biased agonist, NLX-204, shows rapid-acting antidepressant-like properties and neurochemical changes in two mouse models of depression. Behav Brain Res. 2023 Feb 13;438:114207. doi: 10.1016/j.bbr.2022.114207. Epub 2022 Nov 8. PMID: 36368443.
1: Sniecikowska J, Głuch-Lutwin M, Bucki A, Więckowska A, Siwek A, Jastrzębska-Więsek M, Partyka A, Wilczyńska D, Pytka K, Pociecha K, Cios A, Wyska E, Wesołowska A, Pawłowski MH, Varney M, Newman-Tancredi A, Kołaczkowski M. Novel aryloxyethyl derivatives of 1-(1-benzoylpiperidin-4-yl)methanamine as the Extracellular Regulated Kinases 1/2 (ERK1/2) phosphorylation-preferring serotonin 5 HT1A receptor biased agonists with robust antidepressant-like activity. J Med Chem. 2019 Feb 5. doi: 10.1021/acs.jmedchem.9b00062. [Epub ahead of print] PubMed PMID: 30721053.